Tag: NV103
NanoValent Receives Patent for Targeted Polymerized Nanoparticles in Cancer Treatment
NanoValent Pharmaceuticals, a development stage pharmaceutical company progressing a new class of therapeutic anti-cancer agents called targeted nanospheres (TNS), has received United States Patent...
NanoValent Pharmaceuticals and Children’s Hospital Los Angeles Sign Exclusive Global Licensing...
Earlier today, NanoValent Pharmaceuticals, a privately-held development-stage cancer-focused pharmaceutical company advancing antibody-drug conjugate or ADC therapeutics, confirmed signing a licensing agreement with Children's Hospital...